My BIO investments in the large caps has never compelled me to improve my understanding of this process until I invested in this micro cap stock.
Help me out here. Pardon any ignorance. Are you suggesting some patients from the control arm began to progress so they were switched to a different treatment regimen and thus that could have a barring on the out performing arm. If so how can we get a comparative analysis if another i/o is introduced. Of coarse it would be best for the patient.
Pretty simple even for a layperson. The bavi arm is performing as expected but will not meet the assumptions tha it would beat the control arms to the extent expected. This I's due to control arm overachieving their expected results. Most likely due to there being new third line I/O drugs for control group to opt for after being told they are progressing